HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Changes in sex behaviour after menopause: effects of tibolone.
In order to analyse both sexual desire after menopause and its response to treatment with tibolone , a r and omized placebo/tibolone trial has been design ed with 28 postmenopausal patients . They were asked to answer a question naire design ed by us to obtain quantitative measurements to describe changes in sexual desire . After selection , the patients were r and omly assigned to two groups as follows : 14 in the group treated with 2.5 mg/day of tibolone and 14 in the placebo group treated with 500 mg/day of calcium . The patients were monitored after 3 , 6 and 12 months . Before joining this study , they had signed a written consent . It was observed that the sexual desire after menopause underwent a significant fall , with decline in arousability and intercourse . The comparative results show that the patients treated with tibolone experience an improvement after the third month of treatment and this improvement was maintained until the end of treatment . We conclude that the question naire proposed here is a useful non-parametric method to diagnose a patient 's sexuality status at the baseline assessment and a valuable tool for monitoring various therapies . Furthermore , tibolone proved to be effective in managing reduced sexual desire which appears in postmenopausal patients
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .